Abstract
Reshaping the immune balance by adoptive transfer of regulatory T-cells (Tregs) has emerged as a promising strategy to combat undesired immune reactions, including in Graft-versus-Host Disease (GvHD), which is the most lethal non-relapse complication of allogeneic hematopoietic stem cell transplantation. Currently however, little is known about the potentially inhibitory in vivo effects of conventional immunosuppressive drugs, which are routinely used to treat GvHD, on adoptively transferred Tregs. Here we demonstrate drug-specific effects of the conventional immunosuppressive drugs Cyclosporine A, Mycophenolate mofetil and methylprednisolone on adoptively transferred Tregs in a humanized NOD/SCID/IL2Rgamma-/- GvHD mouse model. The clinical course of GvHD and postmortem organ histology, including cellular organ infiltration, showed that co-administration of Cyclosporine A and Tregs is highly beneficial as it enhanced Treg accumulation at inflammatory sites like lung and liver. Similarly, co-administration of Mycophenolate mofetil and Tregs improved clinical signs of GvHD. In contrast, co-administration of methylprednisolone and Tregs resulted in reduced Treg recruitment to inflammatory sites and the fast deterioration of some animals. Consequently, when clinical trials investigating safety and efficacy of adjunctive Treg therapy in GvHD are designed, we suggest co-administering Cyclosporine A, whereas high doses of glucocorticosteroids should be avoided.
Highlights
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for many patients with malignant and non-malignant diseases of the hematopoietic system
To investigate the clinical effect of conventional immunosuppressive drugs on adjunctive tTreg therapy, Graft-versus-Host Disease (GvHD) was induced in NOD/ SCID/IL-2Rgamma-/- mice by infusion of 3x106 human peripheral blood mononuclear cells (PBMCs) (Figure 1, Table 1 and Figures 2A–M)
The timing of clinical GvHD manifestation resembled the clinical course known from human HSCT, with disease onset usually occurring during the first 15 days after transplantation
Summary
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for many patients with malignant and non-malignant diseases of the hematopoietic system. Graftversus Host-Disease (GvHD) still constitutes one of the most lethal post-transplant complications of HSCT [1]. The current paradigm holds that GvHD is primarily a T-cell mediated disease caused by donor effector-T-lymphocytes recognizing allogenic structures as non-self in the host, and thereby eliciting their proinflammatory and cytolytic program. Therapeutic benefits can be achieved by enrichment of circulating tTregs after HSCT [12,13,14,15,16,17,18,19] and in the context of solid organ transplantation [20,21,22] and autoimmune diseases such as hepatitis C vasculitis [23], systemic lupus erythematosus or Type 1 diabetes [24,25,26]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.